Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Asparaginase
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Clinigen Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Porton Biopharma Limited Licenses Erwinase® to Clinigen
Details : Under the terms of the agreement, Clinigen will distribute Erwinase®/ Erwinaze®, the Porton's life-saving treatment for acute lymphoblastic leukaemia.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Undisclosed
April 16, 2020
Lead Product(s) : Asparaginase
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Clinigen Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : BW-1010
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : BlueWillow Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 01, 2019
Lead Product(s) : BW-1010
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : BlueWillow Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
